Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?
Mounting evidence suggests that insulin therapy may reduce risk for CV events while preserving beta-cell function, and several continuing long-term CV trials are testing these hypotheses explicitly.
Gerstein
Hertzel C
HC
Division of Endocrinology and Metabolism and the Population Health Research Institute, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, ON L8N 3Z5, Canada. gerstein@mcmaster.ca
Rosenstock
Julio
J
D002318:Cardiovascular Diseases / Q000150:complications* / Q000378:metabolism / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D006943:Hyperglycemia / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D007328:Insulin / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000378:metabolism*
D007328:Insulin